Our News

Press Releases

Tolero is a leading developer of novel therapeutics to inhibit biologic drivers of oncologic and hematologic diseases. A list of recent press releases and other news from Tolero can be found below. We welcome inquiries about our pathway-centric pipeline and our novel approach to drug discovery. To contact our media relations staff, click here.

October 29, 2019

Tolero Pharmaceuticals Presents Findings from Preclinical Studies Evaluating Investigational Agents TP-1287 in Prostate Cancer Models and TP-1454 in Colorectal Cancer Models (More)

September 28, 2019

Tolero Pharmaceuticals Presents Preliminary Findings from Phase 1 Study Evaluating Investigational Agent TP-0903 in Patients with Advanced Solid Tumors at ESMO 2019 (More)

June 14, 2019

Tolero Pharmaceuticals Presents Clinical Data from Ongoing Phase 1 Zella 101 Study Evaluating Investigational Agent Alvocidib in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed AML at EHA 2019 (More)

June 12, 2019

Tolero Pharmaceuticals Announces First Patient Dosed with Investigational Agent TP-0903 in Phase 1/2 Study in Patients with Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma  (More)

May 30, 2019

Tolero Pharmaceuticals Advances Investigational Agent TP-0903 into Phase 1b Expansion Stage of Study in Patients with Advanced Solid Tumors (More)

May 16, 2019

Tolero Pharmaceuticals to Highlight Clinical Data Evaluating Investigational Agent Alvocidib in Patients with Newly Diagnosed AML at EHA 2019 (More)

May 14, 2019

Tolero Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of Investigational Agent TP-3654 in Patients with Advanced Solid Tumors  (More)

February 27, 2019

Tolero Pharmaceuticals to Present New Data Evaluating Investigational Agents TP-0903 and TP-0184 at AACR Annual Meeting 2019 (More)

January 10, 2019

Tolero Pharmaceuticals Announces First Patient Dosed with Investigational Agent TP-1287 in Phase 1 Study in Patients with Advanced Solid Tumors (More)

December 1, 2018

Tolero Pharmaceuticals Presents Updated Clinical Data from Ongoing Phase 2 Zella 201 Study Evaluating Investigational Agent Alvocidib in Patients with MCL-1 Dependent Relapsed or Refractory AML at ASH 2018 (More)

November 15, 2018

Tolero Pharmaceuticals Presents Clinical Data of AXL Kinase Inhibitor TP-0903 Showing its Ability to Enhance Host Immune Responses to Tumors (More)

November 2, 2018

Tolero Pharmaceuticals to highlight new data evaluating investigational agents Alvocidib and TP-1287 at 2018 American Society of Hematology annual meeting (More)

October 16, 2018

Tolero Pharmaceuticals announces first patient dosed with investigational agent Alvocidib in phase 1b/2 Zella 102 study in patients with myelodysplastic syndromes (MDS) (More)

August 17, 2018

Tolero Pharmaceuticals announces clinical research collaboration with AbbVie for acute myeloid leukemia trial.  (More)

July 25, 2018

Tolero Pharmaceuticals announces first patient dosed with investigational agent TP-0184, an activin A receptor type 1 (ACVR1) inhibitor, in phase 1 study of patients with advanced solid tumors  (More)

July 23, 2018

Tolero Pharmaceuticals advances investigational agent alvocidib into second stage of phase 2 Zella 201 study in patients with relapsed refractory MCL-1–dependent AML  (More)

June 15, 2018

Tolero Pharmaceuticals presents clinical data for investigational agent alvocidib in patients with relapsed refractory MCL-1—dependent AML at EHA 2018  (More)

May 18, 2018

Tolero Pharmaceuticals to present clinical data evaluating investigational agent alvocidib in patients with relapsed refractory MCL-1—dependent AML at EHA 2018  (More)

April 13, 2018

Tolero Pharmaceuticals to present preclinical data supporting apoptosis—inducing activity of alvocidib in acute myeloid leukemia  (More)

November 10, 2017

Tolero Pharmaceuticals opens new headquarters in Lehi  (More)

October 23, 2017

Tolero Pharmaceuticals announces preclinical data supporting development of TP-1287 and TP-3654 for MYC-dependent triple-negative breast cancer  (More)

October 5, 2017

Tolero Pharmaceuticals to deliver keynote presentations at the 9th International Conference on Leukemia and Hematologic Oncology  (More)

June 21, 2017

Tolero Pharmaceuticals to expand enrollment of phase II study of alvocidib in MCL-1–dependent AML into Europe  (More)

June 15, 2017

Tolero Pharmaceuticals to present supportive preclinical data for investigational CDK inhibitor alvocidib at European Hematology Association annual meeting  (More)

April 5, 2017

Tolero Pharmaceuticals presents preclinical data on CDK9 inhibitor alvocidib and its prodrug, TP-1287, at AACR 2017 (More)

January 26, 2017

Sumitomo Dainippon Pharma completes acquisition of Tolero Pharmaceuticals, Inc (US biotechnology company)  (More)

Want to know more? Read about our latest findings.